Jazz Pharmaceuticals agreed to buy Actio Biosciences in a deal valued at just over $1.3 billion, including $820 million upfront and up to $500 million more tied to regulatory and sales milestones. Actio’s lead program, ABS-1230, targets KCNT1-related epilepsy, a condition with no FDA-approved treatments.